Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) Helping Smokers Light Up Less
- Poised to revolutionize smokeless tobacco
- Proven effective in cannabinoid delivery, undergoing testing for nicotine
- An enabling tech seeking third-party partnerships within the tobacco industry
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is helping smokers light up less. Using LXRP’s revolutionary technology, smokers could be able to give up smoking without giving up nicotine. With one billion smokers worldwide, companies are seeking safer delivery technologies to help wean smokers from this deadly habit. Through third-party partnerships with major tobacco industry players, LXRP is poised to revolutionize smokeless tobacco (http://nnw.fm/qwD6f).
Lexaria is gaining prominence for its proprietary delivery technology. The company’s DehydraTECH™ technology, already proven effective in cannabinoid delivery, is undergoing testing for nicotine. Smoking is harmful due to the 4,000 chemicals released when the tobacco is lit up, even though the amount of nicotine absorbed by smokers represents a minimal hazard. Inhalation through the lungs is not healthy. Non-combusted food and drink through the human GI have been found to be much safer. However, previous methods of infusing tobacco in gum, mints or coffee have irritated the gastrointestinal tract, creating cramps and other symptoms, and required sweeteners to mask the bitter taste.
LXRP’s technology enables the delivery of bioactive substances via oral ingestion without the need for the unhealthy practice of inhalational dosing or the addition of unhealthy sugars or sweeteners. In addition, DehydraTECH acts as a Trojan horse, allowing the drug to enter the GI tract, and it is expected to reduce or eliminate uncomfortable side effects that smokers have experienced through previous edible food formats. DehydraTECH is powerful at accelerating intestinal absorption, having already been proven to decrease delivery-time to the bloodstream of edible cannabinoids from the previous 60-90 minutes to a mere 10-15 minutes.
Following its established model in the cannabis industry, Lexaria’s aim is to partner with tobacco companies rather than compete with them. It is an enabling tech, not a competing tech. In the cannabis industry, the company has entered into a licensing agreement with Biolog, Inc. (a Utah-based company not to be confused with a California cell phenotyping company of the same name) to create a unique set of next-generation food and beverage cannabis-infused products for the U.S. market. LXRP also recently entered into an agreement with Cannfections Group Inc. to create cannabis-infused chocolates and candies for the Canadian market.
Lexaria is now looking to out-license its DehydraTECH to third-party partners in the tobacco industry. These partnerships could pave the way for a healthier smoke-free option for the one billion smokers worldwide. Lexaria is the only company in the world that holds a patent for this oral technology, including the pill. A new U.S. patent award protects this nicotine delivery system, creating a path for what could be the world’s first nicotine edibles for the smokeless tobacco industry.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
- Poised to revolutionize smokeless tobacco
- Proven effective in cannabinoid delivery, undergoing testing for nicotine
- An enabling tech seeking third-party partnerships within the tobacco industry
Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is helping smokers light up less. Using LXRP’s revolutionary technology, smokers could be able to give up smoking without giving up nicotine. With one billion smokers worldwide, companies are seeking safer delivery technologies to help wean smokers from this deadly habit. Through third-party partnerships with major tobacco industry players, LXRP is poised to revolutionize smokeless tobacco (http://nnw.fm/qwD6f).
Lexaria is gaining prominence for its proprietary delivery technology. The company’s DehydraTECH™ technology, already proven effective in cannabinoid delivery, is undergoing testing for nicotine. Smoking is harmful due to the 4,000 chemicals released when the tobacco is lit up, even though the amount of nicotine absorbed by smokers represents a minimal hazard. Inhalation through the lungs is not healthy. Non-combusted food and drink through the human GI have been found to be much safer. However, previous methods of infusing tobacco in gum, mints or coffee have irritated the gastrointestinal tract, creating cramps and other symptoms, and required sweeteners to mask the bitter taste.
LXRP’s technology enables the delivery of bioactive substances via oral ingestion without the need for the unhealthy practice of inhalational dosing or the addition of unhealthy sugars or sweeteners. In addition, DehydraTECH acts as a Trojan horse, allowing the drug to enter the GI tract, and it is expected to reduce or eliminate uncomfortable side effects that smokers have experienced through previous edible food formats. DehydraTECH is powerful at accelerating intestinal absorption, having already been proven to decrease delivery-time to the bloodstream of edible cannabinoids from the previous 60-90 minutes to a mere 10-15 minutes.
Following its established model in the cannabis industry, Lexaria’s aim is to partner with tobacco companies rather than compete with them. It is an enabling tech, not a competing tech. In the cannabis industry, the company has entered into a licensing agreement with Biolog, Inc. (a Utah-based company not to be confused with a California cell phenotyping company of the same name) to create a unique set of next-generation food and beverage cannabis-infused products for the U.S. market. LXRP also recently entered into an agreement with Cannfections Group Inc. to create cannabis-infused chocolates and candies for the Canadian market.
Lexaria is now looking to out-license its DehydraTECH to third-party partners in the tobacco industry. These partnerships could pave the way for a healthier smoke-free option for the one billion smokers worldwide. Lexaria is the only company in the world that holds a patent for this oral technology, including the pill. A new U.S. patent award protects this nicotine delivery system, creating a path for what could be the world’s first nicotine edibles for the smokeless tobacco industry.
For more information, visit the company’s website at www.LexariaBioscience.com
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
